Lorca Luz, Puga Larrain Barbara, Leao Ribeiro Ivana, Gonzalez Valdivia Ivana, Fernández Hermoso Angelia, Bass Maturana Francisca, Canelo Lazcano Francisco
Department of Physical Medicine and Rehabilitation, Hospital del Salvador, Santiago, Chile.
Department of Intensive Hematology, Hospital del Salvador, Santiago, Chile.
Hematol Transfus Cell Ther. 2025 Jul-Sep;47(3):103933. doi: 10.1016/j.htct.2025.103933. Epub 2025 Aug 2.
Hematopoietic stem cell transplantation (HSCT) is a treatment option for patients with hematologic malignancies. The aim of this study is to validate the Hematopoietic Cell Transplantation Frailty Scale in a Chilean population.
This was a cross-sectional scale validation study. The sample consisted of patients with various hematologic malignancies who were transplantation candidates. The study had two stages: (1) translation (forward and backward) and (2) psychometric analysis, including face validity, test-retest reliability, and content validity. Descriptive analyses included mean, standard deviation, and the 95 % confidence interval. Reliability was assessed with Spearman's correlation, and content validity used Kendall's W test.
Fifty-four patients (53.7 % women) were included, with multiple myeloma being the most frequent diagnosis (33.3 %). Positive and strong correlations were identified (Spearman's Rho [ρ]: 1.0; p-value <0.001) for all items on the scale. Regarding content validity, there was agreement among evaluators for the categories of relevance and coherence (p-value <0.01; Kendall's W range: 0.13-0.17) but not for "clarity" (p-value = 0.11; Kendall's W: 0.07). Some terms in the content were adjusted without affecting the overall structure of the scale. In the retest analysis, descriptive values were similar to the initial test.
The Spanish version of the Hematopoietic Cell Transplantation Frailty Scale for Chile is conceptually and linguistically equivalent to the original instrument. Additionally, it demonstrated adequate psychometric properties in terms of validity and reliability.
造血干细胞移植（HSCT）是血液系统恶性肿瘤患者的一种治疗选择。本研究的目的是在智利人群中验证造血细胞移植虚弱量表。
这是一项横断面量表验证研究。样本包括各种血液系统恶性肿瘤且符合移植条件的患者。该研究分两个阶段进行：（1）翻译（正向和反向），（2）心理测量分析，包括表面效度、重测信度和内容效度。描述性分析包括均值、标准差和95%置信区间。信度用Spearman相关性评估，内容效度用Kendall's W检验。
纳入了54例患者（53.7%为女性），最常见的诊断是多发性骨髓瘤（33.3%）。量表所有项目均呈现正且强的相关性（Spearman's Rho [ρ]：1.0；p值<0.001）。关于内容效度，评估者在相关性和连贯性类别上达成了一致（p值<0.01；Kendall's W范围：0.13 - 0.17），但在“清晰度”方面未达成一致（p值 = 0.11；Kendall's W：0.07）。对内容中的一些术语进行了调整，未影响量表的整体结构。在重测分析中，描述性值与初始测试相似。
智利版造血细胞移植虚弱量表在概念和语言上与原量表等效。此外，它在效度和信度方面表现出足够的心理测量特性。
